This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Oleson, F. B.
Right arrow Articles by Tally, F. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Oleson, F. B., Jr.
Right arrow Articles by Tally, F. P.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, November 2000, p. 2948-2953, Vol. 44, No. 11
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.

Once-Daily Dosing in Dogs Optimizes Daptomycin Safety

F. B. Oleson Jr.,1,* C. L. Berman,2 J. B. Kirkpatrick,3 K. S. Regan,3 J.-J. Lai,1 and F. P. Tally1

Cubist Pharmaceuticals, Inc., Cambridge,1 and Consultant, Wayland,2 Massachusetts, and WIL Research Laboratories, Ashland, Ohio3

Received 21 September 1999/Returned for modification 17 January 2000/Accepted 15 July 2000

Daptomycin is a novel lipopeptide antibiotic with potent bactericidal activity against most clinically important gram-positive bacteria, including resistant strains. Daptomycin has been shown to have an effect on skeletal muscle. To guide the clinical dosing regimen with the potential for the least effect on skeletal muscle, two studies were conducted with dogs to compare the effects of repeated intravenous administration every 24 h versus every 8 h for 20 days. The data suggest that skeletal-muscle effects were more closely related to the dosing interval than to either the maximum concentration of the drug in plasma or the area under the concentration-time curve. Both increases in serum creatine phosphokinase activity and the incidence of myopathy observed at 25 mg/kg of body weight every 8 h were greater than those observed at 75 mg/kg every 24 h despite the lower maximum concentration of drug in plasma. Similarly, the effects observed at 25 mg/kg every 8 h were greater than those observed at 75 mg/kg every 24 h at approximately the same area under the concentration-time curve from 0 to 24 h. Once-daily administration appeared to minimize the potential for daptomycin-related skeletal-muscle effects, possibly by allowing for more time between doses for repair of subclinical effects. Thus, these studies with dogs suggest that once-daily dosing of daptomycin in humans should have the potential to minimize skeletal-muscle effects. In fact, interim results of ongoing clinical trials, which have focused on once-daily dosing, appear to be consistent with this conclusion.

* Corresponding author. Mailing address: Cubist Pharmaceuticals, Inc., 24 Emily St., Cambridge, MA 02139. Phone: (617) 576-1999. Fax: (617) 576-0271. E-mail: roleson{at}cubist.com.

Antimicrobial Agents and Chemotherapy, November 2000, p. 2948-2953, Vol. 44, No. 11
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Odero, R. O., Cleveland, K. O., Gelfand, M. S. (2009). Rhabdomyolysis and acute renal failure associated with the co-administration of daptomycin and an HMG-CoA reductase inhibitor. J Antimicrob Chemother 63: 1299-1300 [Full Text]  
  • Hawkey, P. M. (2008). Pre-clinical experience with daptomycin. J Antimicrob Chemother 62: iii7-iii14 [Abstract] [Full Text]  
  • Warren, R. E. (2008). Daptomycin in endocarditis and bacteraemia: a British perspective. J Antimicrob Chemother 62: iii25-iii33 [Abstract] [Full Text]  
  • Ponticelli, C. (2008). New recommendations in the treatment of Gram-positive bacteraemia in dialysis patients. Nephrol Dial Transplant 23: 27-32 [Full Text]  
  • Lemaire, S., Van Bambeke, F., Mingeot-Leclercq, M.-P., Tulkens, P. M. (2007). Modulation of the Cellular Accumulation and Intracellular Activity of Daptomycin towards Phagocytized Staphylococcus aureus by the P-Glycoprotein (MDR1) Efflux Transporter in Human THP-1 Macrophages and Madin-Darby Canine Kidney Cells. Antimicrob. Agents Chemother. 51: 2748-2757 [Abstract] [Full Text]  
  • Falagas, M. E., Giannopoulou, K. P., Ntziora, F., Vardakas, K. Z. (2007). Daptomycin for endocarditis and/or bacteraemia: a systematic review of the experimental and clinical evidence. J Antimicrob Chemother 60: 7-19 [Abstract] [Full Text]  
  • Cobb, E., Kimbrough, R. C, Nugent, K. M, Phy, M. P (2007). Organizing Pneumonia and Pulmonary Eosinophilic Infiltration Associated with Daptomycin. The Annals of Pharmacotherapy 41: 696-701 [Abstract] [Full Text]  
  • Vouillamoz, J., Moreillon, P., Giddey, M., Entenza, J. M. (2006). Efficacy of daptomycin in the treatment of experimental endocarditis due to susceptible and multidrug-resistant enterococci. J Antimicrob Chemother 58: 1208-1214 [Abstract] [Full Text]  
  • Kazory, A., Dibadj, K., Weiner, I. D. (2006). Rhabdomyolysis and acute renal failure in a patient treated with daptomycin. J Antimicrob Chemother 57: 578-579 [Full Text]  
  • Huang, V., Rybak, M. J. (2006). Evaluation of daptomycin activity against Staphylococcus aureus in an in vitro pharmacodynamic model under normal and simulated impaired renal function. J Antimicrob Chemother 57: 116-121 [Abstract] [Full Text]  
  • Schriever, C. A., Fernandez, C., Rodvold, K. A., Danziger, L. H. (2005). Daptomycin: A novel cyclic lipopeptide antimicrobial. Am J Health Syst Pharm 62: 1145-1158 [Abstract] [Full Text]  
  • Duh, M. S., Lefebvre, P., Fastenau, J., Piech, C. T., Waltzman, R. J. (2005). Assessing the Clinical Benefits of Erythropoietic Agents Using Area Under the Hemoglobin Change Curve. The Oncologist 10: 438-448 [Abstract] [Full Text]  
  • Schriever, C., Zeitz-Colaizzi, L., Quinn, A., Schriever, A. E., Cannon, J. P. (2005). Considerations for the Management of Gram-Positive Pathogens in the Intensive Care Unit. Journal of Pharmacy Practice 18: 100-108 [Abstract]  
  • Echevarria, K., Datta, P., Cadena, J., Lewis, J. S. II (2005). Severe myopathy and possible hepatotoxicity related to daptomycin. J Antimicrob Chemother 55: 599-600 [Full Text]  
  • Steenbergen, J. N., Alder, J., Thorne, G. M., Tally, F. P. (2005). Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections. J Antimicrob Chemother 55: 283-288 [Abstract] [Full Text]  
  • Dvorchik, B. H., Damphousse, D. (2005). The Pharmacokinetics of Daptomycin in Moderately Obese, Morbidly Obese, and Matched Nonobese Subjects. J Clin Pharmacol 45: 48-56 [Abstract] [Full Text]  
  • Veligandla, S. R, Louie, K. R, Malesker, M. A, Smith, P. W (2004). Muscle Pain Associated with Daptomycin. The Annals of Pharmacotherapy 38: 1860-1862 [Abstract] [Full Text]  
  • Dvorchik, B. (2004). Moderate Liver Impairment Has No Influence on Daptomycin Pharmacokinetics. J Clin Pharmacol 44: 715-722 [Abstract] [Full Text]  
  • Safdar, N., Andes, D., Craig, W. A. (2004). In Vivo Pharmacodynamic Activity of Daptomycin. Antimicrob. Agents Chemother. 48: 63-68 [Abstract] [Full Text]  
  • Vaudaux, P., Francois, P., Bisognano, C., Li, D., Lew, D. P., Schrenzel, J. (2003). Comparative efficacy of daptomycin and vancomycin in the therapy of experimental foreign body infection due to Staphylococcus aureus. J Antimicrob Chemother 52: 89-95 [Abstract] [Full Text]  
  • Cha, R., Grucz, R. G. Jr., Rybak, M. J. (2003). Daptomycin Dose-Effect Relationship against Resistant Gram-Positive Organisms. Antimicrob. Agents Chemother. 47: 1598-1603 [Abstract] [Full Text]  
  • Sakoulas, G., Eliopoulos, G. M., Alder, J., Eliopoulos, C. T. (2003). Efficacy of Daptomycin in Experimental Endocarditis Due to Methicillin-Resistant Staphylococcusaureus. Antimicrob. Agents Chemother. 47: 1714-1718 [Abstract] [Full Text]  
  • Dvorchik, B. H., Brazier, D., DeBruin, M. F., Arbeit, R. D. (2003). Daptomycin Pharmacokinetics and Safety following Administration of Escalating Doses Once Daily to Healthy Subjects. Antimicrob. Agents Chemother. 47: 1318-1323 [Abstract] [Full Text]  
  • Petersen, P. J., Bradford, P. A., Weiss, W. J., Murphy, T. M., Sum, P. E., Projan, S. J. (2002). In Vitro and In Vivo Activities of Tigecycline (GAR-936), Daptomycin, and Comparative Antimicrobial Agents against Glycopeptide-Intermediate Staphylococcus aureus and Other Resistant Gram-Positive Pathogens. Antimicrob. Agents Chemother. 46: 2595-2601 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»